ENG: Endoglin
Vascular endothelium glycoprotein that plays an important role in the regulation of angiogenesis.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on ENG, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Carotuximab | Phase 3 | Tracon Pharmaceuticals | Antibody | InhibitorEndoglin inhibitor | 2 |
| Study of AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate Canc | Carotuximab | Phase 2 | Recruiting | Edwin Posadas, MD | Sep 9, 2022 |
| Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer | Carotuximab | Phase 1 | Recruiting | Karen Reckamp, MD, MS | Jun 2, 2022 |
- Telangiectasia, hereditary hemorrhagic, type 10.85
- Hereditary hemorrhagic telangiectasia0.84
- Vascular disorder0.60
- Arteriovenous hemangioma/malformation0.59
- Capillary disorder0.58
- Capillary malformation0.57
- Congenital anomaly of the great arteries0.57
- Abnormality of the cardiovascular system0.56
- Abnormality of the vasculature0.55
- Congenital anomaly of cardiovascular system0.55
- Abnormal cardiovascular system morphology0.55
- Congenital vascular malformation0.53
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3712885, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P17813, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets